Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Diabetes

Glucagon Emergency Kit Recalled Due to Loss of Potency

Brian Park, PharmD

October 4, 2021

The use of affected product may fail to treat patients with severe hypoglycemia due to a loss of potency.

Diabetes

Warning Letters Sent to Companies Selling Supplements Claiming to Treat Diabetes

Brian Park, PharmD

September 16, 2021

The FDA has not evaluated these products for safety or effectiveness.

General Medicine

FDA to Review Relugolix Combination Therapy for Endometriosis Pain

Brian Park, PharmD

September 15, 2021

The application is supported by data from the phase 3 SPIRIT program, which includes the SPIRIT 1 and SPIRIT 2 studies, as well as an open-label extension study.

Practice Management

FDA Issues Marketing Denial Orders for Flavored E-Cigarette Products

Brian Park, PharmD

September 9, 2021

The MDOs were issued to approximately 55,000 flavored ENDS products from JD Nova Group LLC, Great American Vapes, and Vapor Salon and included favors such as Apple Crumble, Dr. Cola and Cinnamon Toast Cereal.

General Medicine

Pfizer, BioNTech Submit Supplemental BLA for COVID-19 Vaccine Booster

Brian Park, PharmD

September 9, 2021

The application includes data from a phase 3 trial that evaluated a booster dose of Comirnaty in 306 adult participants 18 to 55 years of age who were previously vaccinated with a 2-dose primary regimen.

Thyroid

Additional Dosing Options of Tirosint-SOL Now Available

Brian Park, PharmD

September 1, 2021

Tirosint-SOL is approved for the treatment of hypothyroidism and for pituitary thyrotropin suppression.

Diabetes

FDA Approves New Formulation of Gvoke for Severe Hypoglycemia

Brian Park, PharmD

August 26, 2021

The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older.

General Endocrinology

Long-Acting Monoclonal Antibodies Look Promising for COVID-19 Prevention

Brian Park, PharmD

August 24, 2021

The randomized, double-blind, placebo-controlled, multicenter PROVENT trial included 5197 participants aged 18 years and older who would benefit from AZD7442.

General Medicine

Pfizer Expands Chantix Recall Due to Nitrosamine Impurity

Brian Park, PharmD

August 23, 2021

To date, the Company has not received any reports of adverse events related to this recall.

Diabetes

Lyumjev U-100 Approved for Use in Insulin Pumps

Brian Park, PharmD

August 19, 2021

The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes.

Next post in Diabetes